Objectives: Since 1990s the number of patients diagnosed with endometrial cancer (EC) has doubled. The standard treatment method for treating early endometrial cancer is surgery. Some patients require a subsequent adjuvant therapy. In early endometrial cancers its application is limited to the populations with a high risk of recurrence. The aim of this study was to assess the effectiveness of early endometrial cancer treatment based on an analysis of 5-year follow up of EC patients.
Material and methods: The analysis consisted in a retrospective non-randomized interventional study of patients treated for early endometrial cancer (FIGO stage IA, IB, II). Its end point was either local (small pelvis) or distant recurrence of the disease. Intervention involved an adjuvant treatment applied in selected patients according to the current guidelines for EC treatment. There was no randomization for adjuvant and non-adjuvant EC treatment. The study included a total of 419 patients treated for EC from 2010 to 2012.
Results: The analysis revealed that 108 patients (25.8%) were diagnosed with the recurrent disease. Out of 112 patients treated for stage IA endometrial cancer 32 (28.6%) experienced recurrence. Out of 216 patients at FIGO Stage IB, recurrence was diagnosed in 38 (17.6%). In the group of 91 patients treated for FIGO stage II, EC the recurrence was diagnosed in 38 (41.2%) cases.
Conclusions: Early EC treatment results were unsatisfactory and should be improved. The best outcomes were achieved in patients with IA stage of EC who received a radiation therapy.
Keywords: Treatment Effectiveness Assessment; adjuvant therapy; early endometrial cancer.
An Assessment of Prognostic Factors, Adjuvant Treatment, and Outcomes of Stage IA Polyp-Limited Versus Endometrium-Limited Type II Endometrial Carcinoma.Int J Gynecol Cancer. 2016 Mar;26(3):497-504. doi: 10.1097/IGC.0000000000000635. Int J Gynecol Cancer. 2016. PMID: 26825840 Free PMC article.
Adjuvant radiation therapy is associated with improved overall survival in high-intermediate risk stage I endometrial cancer: A national cancer data base analysis.Gynecol Oncol. 2017 Jan;144(1):119-124. doi: 10.1016/j.ygyno.2016.10.028. Epub 2016 Oct 25. Gynecol Oncol. 2017. PMID: 27793358
Adjuvant radiation in early stage, unfavorable histology endometrial carcinoma is associated with improved local control and survival.Gynecol Oncol. 2014 May;133(2):250-5. doi: 10.1016/j.ygyno.2014.02.032. Epub 2014 Feb 28. Gynecol Oncol. 2014. PMID: 24589416 Clinical Trial.
Adjuvant chemotherapy for advanced endometrial cancer.Cochrane Database Syst Rev. 2014 May 15;2014(5):CD010681. doi: 10.1002/14651858.CD010681.pub2. Cochrane Database Syst Rev. 2014. PMID: 24832785 Free PMC article. Review.
Evolution of adjuvant treatment in endometrial cancer-no evidence and new questions?Strahlenther Onkol. 2018 Nov;194(11):965-974. doi: 10.1007/s00066-018-1339-6. Epub 2018 Aug 15. Strahlenther Onkol. 2018. PMID: 30112692 Review. English.